drug_type
RELEVANT_DRUG
intervention_type
CAR T-cell therapy (cellular gene therapy)
drug_description
Autologous CD19-directed CAR T-cell therapy that redirects patient T cells to recognize and eliminate CD19-positive B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
brexucabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a CD19-specific chimeric antigen receptor bind CD19 on malignant B cells, triggering T‑cell activation, proliferation, cytokine release, and cytotoxic killing of CD19‑positive cells.
drug_name
Brexucabtagene autoleucel (Tecartus)
nct_id_drug_ref
NCT06553872